Alzheimer’s Therapeutics Market Size, Share & Trends Analysis By Product (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Drug, Pipeline Drugs), By End-user, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global alzheimer’s therapeutics market size was valued at USD 4.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 19.99% from 2023 to 2030. The rising prevalence of Alzheimer’s Disease (AD) and approval of disease-modifying therapies are expected to fuel market growth. According to the NCBI, in 2021, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, which is estimated to increase to around 13.8 million by 2060. Women are more prone to be diagnosed with Alzheimer’s disease than men due to the longer life expectancy of women. Moreover, Alzheimer’s disease is becoming the most common cause of death in neurodegenerative diseases and a common cause of physical disability that require immediate treatment.

The impact of the COVID-19 pandemic on the market was negative due to strict measures undertaken by the government such as lockdown to control infection spread. During the pandemic, the prescription rate for drugs used to treat Alzheimer’s was lowered due to a decline in patient visits to clinics and hospitals for treatment and fear of COVID infection, thereby restraining market growth.

The introduction of new highly sensitive cloud-based cognitive assessment systems will assist pharmaceutical companies in identifying the effects of drugs on patients. This will enable pharmaceutical companies to effectively evaluate the cognitive efficacy and safety of pipeline drugs. For instance, Cambridge Cognition’s Cantab Connect product has been specifically developed to measure the effectiveness of drugs for mild, moderate, and prodromal AD. The adoption of such technology is expected to enhance the chances of product approvals, consequently driving the Alzheimer's disease treatment market.

The uncertainty, failure, and discontinuation of the clinical trials of Alzheimer’s drugs lead to the availability of limited treatment alternatives. This increases the costs related to research and development. Hence, it is expected to restrain market growth. For instance, Amgen Inc. and Novartis AG discontinued their Phase 2 clinical trial for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s disease, in July 2019, due to the lack of desired results.

Product Insights

The cholinesterase inhibitors segment held the largest revenue share of over 51.24% in 2022, as it is the standard of care for Alzheimer’s treatment. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc., for the treatment of patients with severe dementia of Alzheimer’s disease (AD). It is a transdermal patch administered once a week and delivers a stable dose of donepezil and was the fourth cholinesterase drug approved and launched in the U.S. Based on product, the market is divided into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs.

The pipeline drugs segment is expected to witness the fastest growth over the forecast period owing to the impending launch of multiple disease-modifying therapies. Companies such as F. Hoffmann La Roche Ltd.; Biogen/Eisai Inc.; and Eli Lilly and Company have drug candidates under development that will modify the treatment landscape of AD. According to Alzheimer’s Association, there were 143 drug candidates in 172 clinical trials for AD. Of these, 31 drug candidates in phase 3 clinical trial, 82 drug candidates in phase 2, and 30 drug candidates in phase 1. Successful completion of trials and subsequent approval of these products are anticipated to boost the market growth.

End-user Insights

The hospital pharmacy segment dominated the market in 2022 with a revenue share of over 57.07% owing to the increasing hospitalization due to a rise in the geriatric population and Alzheimer’s patients. According to Alzheimer’s Association report 2022, there are 518 hospitalizations per 1,000 Medicare beneficiaries in the geriatric population having Alzheimer’s or other dementias as compared to only 234 hospitalizations per 1,000 Medicare beneficiaries without these conditions. However, the total number of hospitalizations of AD patients is expected to remain low compared to the prevalence of Alzheimer’s disease.

The e-commerce segment is expected to expand at a lucrative CAGR over the forecast period. An increase in the usage of the internet and smartphone, ease of ordering medications through an e-commerce platform, and increasing e-commerce services globally are expected to fuel the segment growth in the coming years.

Regional Insights

North America dominated the market with a share of over 40.79% in 2022 and is anticipated to grow at a significant rate over the forecast period. The growing research for the treatment of Alzheimer’s is propelling the market growth. In June 2021, Eisai Co., Ltd. and Biogen’s product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating Alzheimer’s disease, was granted the Breakthrough Therapy designation by the U.S. FDA. Moreover, the increasing government initiatives and funding are expected to boost the growth of the market.

The Asia Pacific region is expected to emerge as the fastest-growing region over the forecast period owing to increasing awareness among people and the increasing research activities to develop novel drugs to treat AD. In 2022, there are around 487,500 Australians living with dementia and this number is expected to increase to 1.1 million by 2058. Dementia is the second leading cause of death in Australia.

Key Companies & Market Share Insights

New product launches and R&D investments are some of the key strategies adopted by the key players to acquire a greater market share. For instance, in January 2023, the FDA approved Eisai Co., Ltd.’s Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease. It reduces amyloid-β plaques and moderately slows mild cognitive decline in patients with early AD. Successful launch of such drugs over the coming years is expected to fuel the market growth. Some prominent players in the global Alzheimer’s therapeutics market include:

• Eisai Co., Ltd.

• Novartis AG

• AbbVie Inc. (Allergan Plc.)

• Adamas Pharmaceuticals, Inc.

• H. Lundbeck A/S

• Biogen

• AC Immune

• F. Hoffmann La Roche Ltd.

• Daiichi Sankyo Company, Limited

• Johnson & Johnson Services, Inc.

• TauRx Pharmaceuticals Ltd.

 Alzheimer’s Therapeutics Market Report Scope

Global Alzheimer’s Therapeutics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global Alzheimer’s therapeutics market report on the basis of product, end-user, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Cholinesterase inhibitors

  • Donepezil

  • Galantamine

  • Rivastigmine

  • NMDA Receptor Antagonist

  • Combination Drug

  • Pipeline Drugs

• End-user Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • E-commerce

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Spain

    • France

    • Italy

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Thailand

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait